Come and join us on 6 July and hear 4 AIM CEO’s speak. Brad George, Orosur CEO updates us on Colombia’s Tier-1 gold mine potential, Cliff Gross, CEO at Tekcapital explains how investors benefit from a special dividend. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,412.00
Bid: 1,411.60
Ask: 1,412.00
Change: 1.00 (0.07%)
Spread: 0.40 (0.03%)
Open: 1,414.20
High: 1,417.40
Low: 1,403.40
Yest. Close: 1,411.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

GSK's ViiV says HIV drug gets rolling probe from US watchdog

Tue, 4th May 2021 14:29

(Alliance News) - GlaxoSmithKline PLC investee ViiV Healthcare on Tuesday said US health regulators have kicked off rolling review of its Cabotegravir HIV prevention drug.

The rolling submission for a new drug application allows ViiV to submit portions of data for regulatory approval from the US Food & Drug Administration. It means ViiV does not have to wait until all data is ready for submission.

Cabotegravir is a HIV pre-exposure prophylaxis, or PrEP, drug. ViiV said submission of the drug will be based on results from two phase IIb/III trials.

"With today's announcement we're one step closer to being able to provide the first, long-acting,

therapy to prevent HIV," ViiV Head of Research & Development Kimberly Smith said.

ViiV is majority-owned by GSK, with Pfizer Inc and Shionogi Ltd also owning stakes.

GSK shares were 0.2% lower at 1,337.26 pence each in London on Tuesday afternoon.

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News

UPDATE 2-U.S. approves Roche drug for emergency use against severe COVID-19

* Re-purposed anti-inflammation drug wins FDA emergency nod* Revenue from Actemra's COVID-19 use has already spiked* Studies of Actemra for COVID had successes, failures (Adds background, comment from company)June 24 (Reuters) - U.S. health regulato...

Today 01:00

Thursday broker round-up

(Sharecast News) - BP: HSBC downgrades to hold with a target price of 360p.

24 Jun 21 14:13

Deutsche upgrades GSK after strategy day

(Sharecast News) - Deutsche Bank upgraded GlaxoSmithKline to 'hold' and raised its target price on the drugmaker's shares after it set out strategic targets.

24 Jun 21 10:16

BROKER RATINGS: Deutsche raises GSK; HSBC cuts BP to Hold

BROKER RATINGS: Deutsche raises GSK; HSBC cuts BP to Hold

24 Jun 21 09:49

TOP NEWS: AstraZeneca prostate cancer drug Lynparza backed in China

TOP NEWS: AstraZeneca prostate cancer drug Lynparza backed in China

24 Jun 21 08:36

LONDON MARKET CLOSE: Stocks edge lower as PMI does little to impress

LONDON MARKET CLOSE: Stocks edge lower as PMI does little to impress

23 Jun 21 17:09

QUOTES-Reaction to GSK's plan to spin off its consumer healthcare business

LONDON, June 23 (Reuters) - GSK set out plans on Wednesday to turn its consumer healthcare business into a separately listed company, aiming to strengthen drug development at its pharmaceuticals business with an 8 billion pound ($11 billion) wind...

23 Jun 21 13:47

TOP NEWS: GSK unveils plans for payout cut and consumer spin-off

TOP NEWS: GSK unveils plans for payout cut and consumer spin-off

23 Jun 21 13:04

GSK sets out ten-year vision, targets sales of £33bn

(Sharecast News) - GlaxoSmithKline is targeting annual sales of more than £33bn once its consumer healthcare arm has been spun out, as it refocuses on vaccines and speciality medicines, the drugs giant announced on Wednesday.

23 Jun 21 12:51

LONDON MARKET MIDDAY: Europe down but oil and mining stocks boost FTSE

LONDON MARKET MIDDAY: Europe down but oil and mining stocks boost FTSE

23 Jun 21 12:11

GSK CEO says to stay on after demerger

LONDON, June 23 (Reuters) - GSK Chief Executive Emma Walmsley plans to stay on as leader of the company after it splits from its consumer healthcare business next year, she said on Wednesday."My focus is resolutely on leading us through this tran...

23 Jun 21 11:58

UPDATE 1-GSK pledges sales boost after split from consumer arm

(Adds details, background)June 23 (Reuters) - New GSK, the pharmaceuticals business being separated from its consumer health operations, pledged to increase sales by more than 5% a year to 2026, the group said on Wednesday, as it published details...

23 Jun 21 11:35

UPDATE 2-GSK's drugs arm to get $11 bln windfall from consumer spin-off

* GSK consumer arm to be demerged in middle of 2022* Drugs business to get 8 bln stg dividend from consumer arm* Lower debt ratio, dividend to boost finances of drugs arm (Adds CEO comment, detail, background)By Ludwig Burger and Pushkala AripakaJun...

23 Jun 21 11:35

UPDATE 3-GSK's drugs arm to get $11 bln booster from consumer spin-off

* GSK consumer arm to be demerged in middle of 2022* Drugs business to get 8 bln stg dividend from consumer arm* Lower debt ratio, dividend to boost finances of drugs arm (Adds details on dividend, debt, Pfizer comment, updates shares)By Ludwig Bur...

23 Jun 21 11:35

GSK sets out plans for listing of consumer products venture

June 23 (Reuters) - Britain's GSK on Wednesday unveiled a detailed plan to spin off its consumer healthcare venture with Pfizer into a separate company by the middle of next year, as the pharmaceutical giant sharpens its focus on prescription med...

23 Jun 21 11:10

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.